The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
The conversation is about using tretinoin cream to improve minoxidil absorption for hair regrowth, specifically in the temple region. The original poster eventually stopped this treatment and switched to oral medication.
Choosing between two hair loss treatments, with a preference for a higher concentration of RU58841 and 5% minoxidil, avoiding oils like castor and argan that may hinder absorption.
The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.
High frequency ultrasonography and HR-MRI can help identify hair shedding causes like inflammation and fibrosis. The conversation discusses the potential of using these technologies to evaluate treatments like Verteporfin for hair regeneration.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
The user has been using minoxidil for over a year with little success, added tretinoin cream, and is considering adding red light therapy. They are advised to use moisturizer to counteract skin sensitivity from tretinoin.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
Hair loss treatment should target dermal white adipose tissue (DWAT) to restore hair follicles. Potential remedies include tocopherol (vitamin E), botox, rosiglitazone, niacin, kojyl cinnamate esters, and ADP355.
RU58841 has significantly improved the user's hair loss experience, alongside oral finasteride, dutasteride, 5 mg minoxidil, topical finasteride, dermastamping, and low-level laser therapy. The user is considering increasing their RU58841 dose from 75 mg to 100-150 mg daily.
A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.
The potential of lowering prolactin levels to regrow hair, with a reference to Bayer's drug HMI 115 which has been indicated as having this effect. Treatments mentioned include Minoxidil and Finasteride, as well as RU58841.
PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.
User added RU58841 to their hair loss treatment and experienced quick results. Others also reported positive effects, but one user experienced chest pains as a side effect.
21-year-old female experiencing hair loss and visible scalp seeks advice on PRP effectiveness. Currently taking spironolactone and krimson for high androgens, unsure if PRP can be done with these medications.
Someone's brother tried Platelet-rich plasma (PRP) for hair loss; it had minimal effect on hair but improved skin appearance. Microneedling at home was suggested as a more sustainable alternative.
RU58841's potential side effects, particularly heart palpitations, are debated, with some attributing them to contamination with minoxidil. Users report mixed experiences, with some seeing no side effects and others cautioning about the lack of reliable data on RU58841's safety.
The conversation discusses buying RU58841 directly from a Chinese supplier for cost savings. It mentions that companies like Anageninc and Actifolic do the same.
RU58841 cured seborrheic dermatitis, oily scalp, dandruff, and scalp pain, improving hair health when combined with Minoxidil. Another user noted diet impacts their seborrheic dermatitis and that finasteride hasn't changed their condition.
PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.
KPV, a peptide patented by L'Oreal, may promote hair growth and reduce hair loss by extending the anagen phase and has anti-inflammatory properties. It could be combined with treatments like minoxidil for enhanced effects.
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.
The user has been using finasteride and minoxidil for almost 2 years with maintenance but no significant regrowth. After adding tretinoin 2 weeks ago, they experienced increased shedding and are seeking advice on whether this is a positive sign.
The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.